Matthew Hewitt | Director, Tumour Immunology & Microenvironment
Bellicum Pharmaceuticals

Matthew Hewitt, Director, Tumour Immunology & Microenvironment, Bellicum Pharmaceuticals

Dr. Matthew Hewitt has held roles in research and development over the past 10 years in both academia and industry. Over that time he has built and run successful programs in pre-clinical, IND-enabling, and clinical support settings using his extensive immunology and molecular biology experience.

Dr. Hewitt is currently Director of the Tumor Immunology & Microenvironment group at Bellicum Pharmaceuticals. His group focuses on understanding the underlying immunology of the tumour microenvironment and examines avenues to overcome it to increase CAR-T efficacy in solid tumours.

Appearances:



World Immunotherapy Congress 2018, Day 1 @ 09:40

Senior-level panel: Immunotherapy strategies for oncology

  • Short 5 minute presentations outlining strategies developing immunotherapy for oncology, given by 6 high level representatives from differing company sizes
  • Panel discussion talking about how strategies for cancer immunotherapy differ between companies, and advantages and disadvantages for both
  • Top level speakers representing big pharma, large biotech and mid-sized biotech

World Immunotherapy Congress 2018, Day 1 @ 15:10

Assessing strategies to neutralize the pro-tumour microenvironment to increase GoCAR-T efficacy in solid tumours

  • The utility of using in-vitro spheroid assays to mimic the in vivo tumour microenvironment to assess strategies in overcoming the pro-tumour microenvironment
  • Assessing the translatability of in vitro models to in vivo rodent models of oncology to guide lead candidate advancement
  • Whether Bellicum’s molecular activation/kill switches engineered into CAR T-cells are resistant to immunosuppressive pathways and increase solid tumour efficacy
last published: 16/Oct/18 13:05 GMT

back to speakers

There are two parts to the Festival of Biologics: the five world-class international conferences covering Antibodies, Immunotherapy, BioSimilars, Clinical Trials, and High Potency APIs; and an exhibition featuring the most exciting technology and solutions for pharma and biotech. There is a registration fee to attend the conferences. To visit the exhibition is free.


Conference 29 - 31 October • Exhibition & Seminars 29 - 31 October 

Sign Up for Event Updates